Navigation Links
Genelabs Technologies Announces Completion of $23.7 Million Registered Direct Financing
Date:10/1/2007

Funds to Support Ongoing HCV Drug Discovery Projects

REDWOOD CITY, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that it has completed its previously announced sale of approximately 12.9 million shares of its common stock and warrants to purchase approximately 2.6 million shares of its common stock for gross proceeds of approximately $23.7 million. Genelabs sold the shares and warrants for $1.84 per unit (each unit consisting of one share and a warrant to purchase 0.20 shares of common stock). The exercise price of the warrants is $2.08 per share. The warrants will be exercisable at any time prior to the fifth anniversary of October 1, 2007. Genelabs plans to use the proceeds from this financing to support its ongoing hepatitis C virus (HCV) drug discovery programs and for general corporate purposes. The proceeds will not be used to fund a new phase III clinical trial of Prestara. Deutsche Bank Securities Inc. acted as exclusive placement agent in the transaction.

A shelf registration statement relating to these securities (File No. 333-145497) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, http://www.sec.gov, or from Genelabs.

Contact: James A. D. Smith

President and Chief Executive Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers Develop Technologies to Devour Food Pathogens
2. Researchers Study Safety of Assisted Reproductive Technologies
3. India to Propose Global Fund for Clean Energy Technologies
4. PM announces a new health care order for India
5. Ramdoss Announces Introduction of RCH-II
6. Britain Announces Third Transfusion Related Mad Cow Case
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Tibet Announces the Dalai Lama’s Tour of South Americ
9. NHS announces further Cost cutting Measures
10. Indian PM Announces Of Setting Up India Study Center At Tashkent
11. PowderMed Announces Needle-Less Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Clarion Safety ... safety labels , has been featured in the National Electrical Manufacturers Association’s ... e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The publication is ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... disease research and education, today announced that it has named Scott Santarella as ... Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he successfully ...
(Date:5/24/2016)... ... 24, 2016 , ... After graduating from Cornell, author Joshua Alexander ... on medication, living on Social Security disability and staying in a group home. In ... It!” (published by Balboa Press), Alexander shares how he was finally able to heal ...
(Date:5/24/2016)... ... ... PhysicianOne Urgent Care, advocators in helping their patients lead the healthiest lives possible, updates ... spring. , The official tick season kicks off in May across the states ... themselves to their prey while they feed off their blood. Like other similar biting ...
(Date:5/24/2016)... ... May 24, 2016 , ... Design Concepts , ... Centro del Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed ... something special for this often overlooked neighborhood. Located at 609 E. 6th Street, ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016  NxStage Medical, Inc. (Nasdaq: ... on advancing renal care, today announced that Jeffrey ... in the following schedule of investor conferences. Where applicable, ... at http://ir.nxstage.com/ .   ... Conference NY, NY           Friday, June 10, 2016 1:30 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... Marziani has joined VMS BioMarketing as senior vice president of sales, announced Andrea ... Marziani will lead the company,s business development and sales team, exploring new opportunities for ... - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: